Preclinical studies suggest that, in certain CML cases, combining allosteric BCR-ABL1 inhibitor Asciminib with a tyrosine kinase inhibitor targeting the ATP site of the fusion kinase can be an effective strategy against resistant (52, 53). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.